Radioactive isotopes xofigo
Ended Awarded Last action
- Contract number
- 36C25624N0388
- Awardee
-
Bayer Healthcare Pharmaceuticals Inc. UEI V1EVGCK7XES8 Part of Bayer Aktiengesellschaft
- Awarding agency
-
Veterans Integrated Service Network 16
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $348,242
Award facts
- Contract value 100% obligated
- $348,241.75 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- Funding agency
- Veterans Integrated Service Network 17 Veterans Health Administration, Department of Veterans Affairs
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Dublin, OH 43017, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$425,478 | |
| Exercise an Option | $386,860 | |
| Other Administrative Action | $0 | |
| Original award | $386,860 |
About this award
Bayer Healthcare Pharmaceuticals Inc. received a delivery order valued at $348,241.75 for Xofigo (radium Ra-223 dichloride), a specialized radiopharmaceutical used to treat castration-resistant prostate cancer. Awarded on December 1, 2023, with an ultimate completion date of September 28, 2025, this firm fixed-price delivery order was issued by Veterans Integrated Service Network 17 (VISN 17), a component of the Department of Veterans Affairs. The contract carries no small business set-aside designation, consistent with Bayer's classification as a large, foreign-owned pharmaceutical enterprise. Performance will occur in Dublin, Ohio.
This delivery order is issued under Bayer Healthcare Pharmaceuticals Inc.'s $840 million multiple-award Federal Supply Schedule contract (FSS-61-IB) for Pharmaceuticals and Drugs with the Department of Veterans Affairs, which streamlines federal procurement of pharmaceutical products at pre-negotiated pricing. The award reflects the Veterans Health Administration's ongoing need for specialized oncology medications to support veteran healthcare programs. Notably, the contract documentation references a deobligation of excess funds for fiscal years 2024 and 2025, indicating budget adjustments within the VA's pharmaceutical procurement operations. Bayer's role as a critical supplier of radiopharmaceuticals and single-source medications positions the company as a key provider within the federal healthcare system's specialized pharmaceutical supply chain.
Quick answers
Who was awarded contract 36C25624N0388?
36C25624N0388 was awarded to Bayer Healthcare Pharmaceuticals Inc. by Veterans Integrated Service Network 16 (Veterans Health Administration) on December 1, 2023.
How much is contract 36C25624N0388 worth?
The government has obligated $348,242 on 36C25624N0388.
Which agency awarded contract 36C25624N0388?
Veterans Integrated Service Network 16 (Veterans Health Administration) awarded 36C25624N0388, with funding from Veterans Integrated Service Network 17 (Veterans Health Administration).
Is contract 36C25624N0388 an order under another contract?
Yes. 36C25624N0388 is a delivery order under 36F79720D0237, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C25624N0388 competed?
The extent of competition for 36C25624N0388 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award